Clinical Trials Browser

Has results × belantamab mafodotin × 1 year × Clear all

NCT04126200 2026-05-06

DREAMM 5

Phase 1/2 Active not recruiting

208 enrolled 5 charts

Multiple Myeloma

NCT07084896 2026-05-06

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM

Phase 1/2 Active not recruiting

106 enrolled 32 charts

Multiple Myeloma

NCT05064358 2026-05-05

DREAMM 14

Phase 2 Completed

177 enrolled 37 charts

Multiple Myeloma, Recurrence

NCT04246047 2026-04-23

DREAMM 7

Phase 3 Active not recruiting

494 enrolled 10 charts 1 FDA

Multiple Myeloma

NCT06868654 2026-04-23

DREAMM 7

Phase 3 Active not recruiting

72 enrolled 10 charts

Multiple Myeloma

NCT06868667 2026-04-23

DREAMM 7

Phase 3 Active not recruiting

24 enrolled 10 charts

Multiple Myeloma

NCT04162210 2026-03-31

DREAMM-3

Phase 3 Active not recruiting

325 enrolled 10 charts

Multiple Myeloma

NCT04676360 2026-03-13

Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma

Phase 2 Terminated

10 enrolled 11 charts

Plasmablastic Lymphoma

NCT03828292 2025-08-19

An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments

Phase 1 Completed

15 enrolled 91 charts

Multiple Myeloma